Drug Profile
Research programme: hematopoietic prostaglandin D2 synthase inhibitors - UniQuest
Alternative Names: Hematopoietic prostaglandin D2 synthase inhibitors; HPGD2S inhibitorsLatest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator University of Queensland
- Developer UniQuest; University of Queensland
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Prostaglandin synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Allergic rhinitis; Asthma; Duchenne muscular dystrophy
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Allergic-rhinitis in Australia (PO)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Asthma in Australia (PO)
- 04 Aug 2016 Research programme: hematopoietic prostaglandin D2 synthase inhibitors - UniQuest is available for licensing -http://uniquest.com.au/filething/get/11945/Prostaglandin%20D2%20Synthase%20Inhibitors%20UniQuest.pdf